Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 15.4% during mid-day trading on Wednesday . The stock traded as high as C$0.24 and last traded at C$0.23. 504,843 shares were traded during mid-day trading, a decline of 19% from the average session volume of 624,324 shares. The stock had previously closed at C$0.20.
Hemostemix Price Performance
The firm’s 50 day moving average price is C$0.10 and its 200-day moving average price is C$0.08. The stock has a market cap of C$27.01 million, a P/E ratio of -15.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Insider Trading – What You Need to Know
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- What is the Euro STOXX 50 Index?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Stock Sentiment Analysis: How it Works
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
